Home > Publications database > p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. > print

001     274419
005     20240229154933.0
024 7 _ |a 10.1002/cjp2.311
|2 doi
024 7 _ |a pmid:36948887
|2 pmid
024 7 _ |a altmetric:144212573
|2 altmetric
037 _ _ |a DKFZ-2023-00586
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Köbel, Martin
|0 0000-0002-6615-2037
|b 0
245 _ _ |a p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
260 _ _ |a Chichester
|c 2023
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1681199148_5540
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 May;9(3):208-222
520 _ _ |a Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a TP53
|2 Other
650 _ 7 |a clear cell
|2 Other
650 _ 7 |a endometrioid
|2 Other
650 _ 7 |a high-grade serous carcinoma
|2 Other
650 _ 7 |a ovarian cancer
|2 Other
650 _ 7 |a p53
|2 Other
650 _ 7 |a prognosis
|2 Other
700 1 _ |a Kang, Eun-Young
|b 1
700 1 _ |a Weir, Ashley
|0 0000-0002-3072-2616
|b 2
700 1 _ |a Rambau, Peter F
|b 3
700 1 _ |a Lee, Cheng-Han
|b 4
700 1 _ |a Nelson, Gregg S
|b 5
700 1 _ |a Ghatage, Prafull
|b 6
700 1 _ |a Meagher, Nicola S
|b 7
700 1 _ |a Riggan, Marjorie J
|b 8
700 1 _ |a Alsop, Jennifer
|b 9
700 1 _ |a Anglesio, Michael S
|0 0000-0003-1639-5003
|b 10
700 1 _ |a Beckmann, Matthias W
|b 11
700 1 _ |a Bisinotto, Christiani
|b 12
700 1 _ |a Boisen, Michelle
|b 13
700 1 _ |a Boros, Jessica
|b 14
700 1 _ |a Brand, Alison H
|b 15
700 1 _ |a Brooks-Wilson, Angela
|b 16
700 1 _ |a Carney, Michael E
|b 17
700 1 _ |a Coulson, Penny
|b 18
700 1 _ |a Courtney-Brooks, Madeleine
|b 19
700 1 _ |a Cushing-Haugen, Kara L
|b 20
700 1 _ |a Cybulski, Cezary
|b 21
700 1 _ |a Deen, Suha
|b 22
700 1 _ |a El-Bahrawy, Mona A
|b 23
700 1 _ |a Elishaev, Esther
|b 24
700 1 _ |a Erber, Ramona
|0 0000-0003-0315-1229
|b 25
700 1 _ |a Fereday, Sian
|b 26
700 1 _ |a Group, AOCS
|b 27
|e Collaboration Author
700 1 _ |a Fischer, Anna
|b 28
700 1 _ |a Gayther, Simon A
|b 29
700 1 _ |a Barquin-Garcia, Arantzazu
|b 30
700 1 _ |a Gentry-Maharaj, Aleksandra
|b 31
700 1 _ |a Gilks, C Blake
|0 0000-0001-7889-8250
|b 32
700 1 _ |a Gronwald, Helena
|b 33
700 1 _ |a Grube, Marcel
|b 34
700 1 _ |a Harnett, Paul R
|b 35
700 1 _ |a Harris, Holly R
|b 36
700 1 _ |a Hartkopf, Andreas D
|b 37
700 1 _ |a Hartmann, Arndt
|b 38
700 1 _ |a Hein, Alexander
|b 39
700 1 _ |a Hendley, Joy
|b 40
700 1 _ |a Hernandez, Brenda Y
|b 41
700 1 _ |a Huang, Yajue
|b 42
700 1 _ |a Jakubowska, Anna
|b 43
700 1 _ |a Jimenez-Linan, Mercedes
|b 44
700 1 _ |a Jones, Michael E
|b 45
700 1 _ |a Kennedy, Catherine J
|b 46
700 1 _ |a Kluz, Tomasz
|b 47
700 1 _ |a Koziak, Jennifer M
|b 48
700 1 _ |a Lesnock, Jaime
|b 49
700 1 _ |a Lester, Jenny
|b 50
700 1 _ |a Lubiński, Jan
|b 51
700 1 _ |a Longacre, Teri A
|b 52
700 1 _ |a Lycke, Maria
|b 53
700 1 _ |a Mateoiu, Constantina
|b 54
700 1 _ |a McCauley, Bryan M
|b 55
700 1 _ |a McGuire, Valerie
|b 56
700 1 _ |a Ney, Britta
|b 57
700 1 _ |a Olawaiye, Alexander
|b 58
700 1 _ |a Orsulic, Sandra
|b 59
700 1 _ |a Osorio, Ana
|b 60
700 1 _ |a Paz-Ares, Luis
|b 61
700 1 _ |a Ramón Y Cajal, Teresa
|b 62
700 1 _ |a Rothstein, Joseph H
|b 63
700 1 _ |a Ruebner, Matthias
|b 64
700 1 _ |a Schoemaker, Minouk J
|b 65
700 1 _ |a Shah, Mitul
|b 66
700 1 _ |a Sharma, Raghwa
|b 67
700 1 _ |a Sherman, Mark E
|b 68
700 1 _ |a Shvetsov, Yurii B
|0 0000-0001-5131-9618
|b 69
700 1 _ |a Singh, Naveena
|b 70
700 1 _ |a Steed, Helen
|b 71
700 1 _ |a Storr, Sarah J
|b 72
700 1 _ |a Talhouk, Aline
|b 73
700 1 _ |a Traficante, Nadia
|b 74
700 1 _ |a Wang, Chen
|b 75
700 1 _ |a Whittemore, Alice S
|b 76
700 1 _ |a Widschwendter, Martin
|b 77
700 1 _ |a Wilkens, Lynne R
|b 78
700 1 _ |a Winham, Stacey J
|b 79
700 1 _ |a Benitez, Javier
|b 80
700 1 _ |a Berchuck, Andrew
|b 81
700 1 _ |a Bowtell, David D
|b 82
700 1 _ |a Candido Dos Reis, Francisco J
|b 83
700 1 _ |a Campbell, Ian
|0 0000-0002-7773-4155
|b 84
700 1 _ |a Cook, Linda S
|b 85
700 1 _ |a DeFazio, Anna
|b 86
700 1 _ |a Doherty, Jennifer A
|b 87
700 1 _ |a Fasching, Peter A
|b 88
700 1 _ |a Fortner, Renée T
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 89
|u dkfz
700 1 _ |a García, María J
|b 90
700 1 _ |a Goodman, Marc T
|b 91
700 1 _ |a Goode, Ellen L
|b 92
700 1 _ |a Gronwald, Jacek
|b 93
700 1 _ |a Huntsman, David G
|0 0000-0003-4934-3322
|b 94
700 1 _ |a Karlan, Beth Y
|b 95
700 1 _ |a Kelemen, Linda E
|b 96
700 1 _ |a Kommoss, Stefan
|b 97
700 1 _ |a Le, Nhu D
|b 98
700 1 _ |a Martin, Stewart G
|b 99
700 1 _ |a Menon, Usha
|b 100
700 1 _ |a Modugno, Francesmary
|b 101
700 1 _ |a Pharoah, Paul Dp
|b 102
700 1 _ |a Schildkraut, Joellen M
|b 103
700 1 _ |a Sieh, Weiva
|b 104
700 1 _ |a Staebler, Annette
|b 105
700 1 _ |a Sundfeldt, Karin
|b 106
700 1 _ |a Swerdlow, Anthony J
|b 107
700 1 _ |a Ramus, Susan J
|b 108
700 1 _ |a Brenton, James D
|b 109
773 _ _ |a 10.1002/cjp2.311
|g p. cjp2.311
|0 PERI:(DE-600)2814357-7
|n 3
|p 208-222
|t The journal of pathology: clinical research
|v 9
|y 2023
|x 2056-4538
909 C O |p VDB
|o oai:inrepo02.dkfz.de:274419
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 89
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-04-16T15:13:41Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-04-16T15:13:41Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2021-04-16T15:13:41Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PATHOL CLIN RES : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-26
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21